MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic 由 Verstovsek, S, Chen, C-C, Egyed, M, Ellis, M, Fox, L, Goh, YT, Gupta, V, Harrison, C, Kiladjian, J-J, Lazaroiu, MC, Mead, A, McLornan, D, McMullin, MF, Oh, ST, Perkins, A, Platzbecker, U, Scheid, C, Vannucchi, A, Yoon, S-S, Kowalski, MM, Mesa, RA

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes 由 Kizhakeyil, A, Zaini, NBM, Poh, ZS, Wong, BHS, Loh, X, Ng, AS, Low, ZS, Prasannan, P, Gong, C, Tan, MGK, Nagarajan, C, Huang, D, Lu, PW, Lim, JQ, Barrans, S, Ong, CK, Lim, ST, Chng, WJ, Follows, G, Hodson, DJ, Du, MQ, Goh, YT, Tan, SH, Grigoropoulos, NF, Verma, NK